RT Journal Article SR Electronic T1 Chronic myelogenous leukemia: The news you have and haven’t heard JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP 913 OP 926 VO 68 IS 11 A1 Matt E. Kalaycio YR 2001 UL http://www.ccjm.org/content/68/11/913.abstract AB Chronic myelogenous leukemia (CML) can usually be cured by bone marrow transplantation from matched donors. Donor T-cell activity from the graft is critical to maintaining remission. Myeloablation may not be necessary for cure. Non-myeloablative but immunosuppressive preparative regimens allow donor engraftment with less toxicity. Early combination therapy with interferon-alfa and cytarabine was the preferred option for patients who could not undergo bone marrow transplantation. Now, the advent of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, promises to change existing treatment paradigms